A team of researchers from Brigham & Women’s Hospital, Mass. Institute of Technology and Mass. General Hospital demonstrated that localizing the delivery of NAMPT inhibitors can extend survival in a mouse model of glioma, according to a paper published this week in the Proceedings of the National Academy of Sciences. The scientists created a test to […]
Nanoparticles
Nanobiotix inks $47m financing to support nanomedicine development
Nanobiotix (PAR:NANO.PA) inked a non-dilutive financial deal with the European Investment Bank last week to support the development of its nanoparticle-based cancer therapies. The Paris, France-based company said it landed a five-year loan to borrow up to €40 million ($46.7 million) contingent upon a set of performance milestones. Nanobiotix plans to use the funds to bring its NBTXR3 […]
Takeda, leon-nanodrugs ink feasibility testing deal for reformulated drug
leon-nanodrugs said today that Takeda (TYO:4502) tapped its MicroJet Reactor technology as part of a feasibility study that could result in the reformulation of one of Takeda’s pipeline products. Using leon’s nanotechnology platform, the companies plan to boost the solubility, bioavailability and stability of one of Takeda’s pipeline products. Positive results from the feasibility study could […]
Ocugen launches Ph3 trial for eye disease nanoemulsion
Ocugen said today that it launched the first of two pivotal Phase III trials for its OCU300 nanoemulsion designed to treat the symptoms of ocular graft versus host disease. The Malvern, Penn.-based company’s drug is a nanoemulsion formulation of brimonidine tartrate made using Ocugen’s OcuNanoE technology. Ocugen touted that it’s the first company to bring […]
Precision NanoSystems raises $6m to fund nanomedicine manufacturing tech
Vancouver-based Precision NanoSystems said today that it closed a $6m Series B round, with investments from 5AM Ventures, Telegraph Hill Partners and Rising Tide Fund. The company is slated to use its newly-acquired funds to support the expansion of its services, including its nanomedicine manufacturing platform, NanoAssemblr. Precision NanoSystems’ technology is designed to enable the […]
MIT researchers devise single-injection delivery method for polio vaccine
Although most of the world is protected from the polio virus thanks to a vaccine developed decades ago, some countries remain vulnerable to the disease thanks to challenges posed by a vaccine that requires repeat dosing. Researchers from the Massachusetts Institute of Technology want to change that with a nanoparticle vaccine that can deliver multiple […]
Will medtech drive the next Southeastern U.S. industrial revolution?
Paul Snyder, Write2Market Once home to a thriving textile industry replete with chemical and mechanical engineers working to improve the soil and machinery converting raw cotton into commercial goods, upstate South Carolina may be on the precipice of its next industrial revolution: medtech. Born from technology developed at the Albert Einstein College of Medicine, Greenville-based […]
NanOlogy looks to transform chemotherapy with localized delivery platform
Paclitaxel revolutionized cancer treatment when it was first used as a chemotherapeutic in the 1990s. But although the product is a powerful cancer killer, patients taking systemic doses of paclitaxel have to endure side effects such as peripheral neuropathy and hair loss. Marc Iacobucci and his team at NanOlogy believe they could replace the need […]
Nanobiotix’s nanoparticle-immunotherapy trial wins FDA approval
Nanobiotix (EMA:NANO) said today that the FDA has approved its IND application for a cancer trial combining its radiotherapy-activated nanoparticle tech with an anti-PD1 antibody. The Phase I/II trial is slated to evaluate the safety and efficacy of Nanobiotix’s NBTXR3 product administered with checkpoint inhibitors in three groups of patients with recurrent or metastatic head and […]
Aura Biosciences raises $30m for nanoparticle cancer treatment
Aura Biosciences has closed a $30 million Series C round with funding from new investors like Arix Bioscience and Lundbeckfonden Ventures, as well as existing investors, including the estate of former-Genzyme CEO Henri Termeer, who died earlier this year. The privately-held biotech is developing a light-activated nanoparticle therapy for patients with ocular melanoma. Aura said […]
